{"protocolSection":{"identificationModule":{"nctId":"NCT00147316","orgStudyIdInfo":{"id":"527-0110"},"organization":{"fullName":"Mitsubishi Tanabe Pharma Corporation","class":"INDUSTRY"},"briefTitle":"Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke","officialTitle":"Japan Alteplase Clinical Trial (J-ACT): Phase 3 Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Acute Ischemic Stroke Within 3 Hours of Onset"},"statusModule":{"statusVerifiedDate":"2012-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2002-04"},"completionDateStruct":{"date":"2003-09"},"studyFirstSubmitDate":"2005-09-05","studyFirstSubmitQcDate":"2005-09-05","studyFirstPostDateStruct":{"date":"2005-09-07","type":"ESTIMATED"},"resultsFirstSubmitDate":"2012-01-19","resultsFirstSubmitQcDate":"2012-01-19","resultsFirstPostDateStruct":{"date":"2012-02-24","type":"ESTIMATED"},"lastUpdateSubmitDate":"2012-02-29","lastUpdatePostDateStruct":{"date":"2012-03-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation","class":"INDUSTRY"},"collaborators":[{"name":"Kyowa Hakko Kogyo Co., Ltd.","class":"INDUSTRY"}]},"descriptionModule":{"briefSummary":"Based on previous studies comparing Duteplase\\[a recombinant tissue plasminogen activator (rt-PA) very similar to alteplase\\] doses, we performed a clinical trial with 0.6mg/kg, which is lower than the internationally approved dosage of 0.9mg/kg, aiming to assess the efficacy and safety of alteplase for the Japanese.","detailedDescription":"Based on previous studies comparing Duteplase ( an rt-PA very similar to alteplase) doses, we performed a clinical trial with 0.6mg/kg, which is lower than the internationally approved dosage of 0.9mg/kg, aiming to assess the efficacy and safety of alteplase for the Japanese.\n\nThe primary endpoints were the rate of patients with mRS score of 0-1 at 3 months and the incidence of sICH within 36 hours. Thresholds for these endpoints were determined by calculating 90% confidence intervals of weighted averages derived from published reports. The protocol was defined according to the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA stroke study with slight modifications."},"conditionsModule":{"conditions":["Cerebral Infarction","Brain Ischemia"],"keywords":["acute stroke","thrombolytic therapy","tissue plasminogen activator"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":103,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Alteplase","type":"EXPERIMENTAL","description":"0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour","interventionNames":["Drug: Alteplase"]}],"interventions":[{"type":"DRUG","name":"Alteplase","description":"0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour","armGroupLabels":["Alteplase"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Patients With a Modified Rankin Scale (mRS) Score of 0-1 at 3 Months","description":"The number of patients with a mRS score of 0-1. The mRS has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability.","timeFrame":"at 3 months"},{"measure":"Number of Patients With Symptomatic Intracranial Hemorrhage (sICH) Within 36 Hours","description":"The number of patients with sICH","timeFrame":"within 36 hours"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPatients with acute ischemic stroke within 3 hours of onset, with a clearly defined time of onset\n\nExclusion Criteria:\n\n1. patients with rapidly improving neurological symptoms or with minor neurological deficit (National Institutes of Health Stroke Scale (NIHSS) score of ≤4) prior to the start of treatment\n2. Computed Tomography (CT) evidence of non-minor early ischemic signs (minor early ischemic sign was defined as the involvement of one-third or less of the middle cerebral artery area)\n3. CT evidence of cerebral hemorrhage or subarachnoid hemorrhage\n4. symptoms suggestive of subarachnoid hemorrhage\n5. lactation, pregnancy or suggestive pregnancy; menstruation\n6. platelet count below 100,000/mm3\n7. heparin administration within 48 hours preceding stroke onset with an elevated activated partial thromboplastin time (APTT); current use of oral anticoagulants with an International Normalized Ratio (INR) of ≥1.7; use of drugs not allowed to be administered concomitantly with alteplase (other thrombolytic agents, ozagrel sodium, argatroban and edaravone) prior to the study treatment\n8. major surgery or serious trauma within the preceding 14 days; serious head or spinal cord trauma within the preceding 3 months\n9. a history of gastrointestinal or urinary tract hemorrhage within the previous 21 days\n10. arterial puncture at a noncompressible site within the preceding 7 days\n11. a history of stroke within the preceding 3 months; a history of intracranial hemorrhage or increased risk of intracranial hemorrhage because of cerebral aneurysm, arteriovenous malformation, neoplasm, etc.\n12. concurrent severe hepatic or renal dysfunction\n13. malignant tumor under treatment\n14. a systolic blood pressure of \\>185 mmHg or diastolic blood pressure of \\>110 mmHg\n15. a need for aggressive treatment to reduce blood pressure to below these limits(14))\n16. blood glucose levels of \\<50 mg/dL or \\>400 mg/dL\n17. acute myocardial infarction(AMI) or endocarditis after AMI\n18. concurrent infectious endocarditis, moya-moya disease (Willis circle occlusion syndrome), aortic dissection, neck trauma, etc.; strong suspicion of ischemic cerebrovascular disorder caused by non-thrombotic occlusion or any other hemodynamic condition\n19. seizure at the onset of stroke\n20. coma (a Japan Coma Scale score of ≥100)\n21. an mRS score of ≥2 before stroke onset\n22. a history of hypersensitivity to protein preparations\n23. difficulty in monitoring for 3 months\n24. less than 3 months since any other clinical trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Takenori Yamaguchi, MD","affiliation":"National Cerebral and Cardiovascular Center, Japan","role":"STUDY_CHAIR"}],"locations":[{"facility":"National Cardiovascular Center","city":"Suita","state":"Osaka","zip":"565-8565","country":"Japan","geoPoint":{"lat":34.76143,"lon":135.51567}}]},"referencesModule":{"references":[{"pmid":"16763187","type":"RESULT","citation":"Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y; Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006 Jul;37(7):1810-5. doi: 10.1161/01.STR.0000227191.01792.e3. Epub 2006 Jun 8."},{"pmid":"21737309","type":"DERIVED","citation":"Hirano T, Sasaki M, Tomura N, Ito Y, Kobayashi S; Japan Alteplase Clinical Trial Group. Low Alberta stroke program early computed tomography score within 3 hours of onset predicts subsequent symptomatic intracranial hemorrhage in patients treated with 0.6 mg/kg Alteplase. J Stroke Cerebrovasc Dis. 2012 Nov;21(8):898-902. doi: 10.1016/j.jstrokecerebrovasdis.2011.05.018. Epub 2011 Jul 7."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Alteplase","description":"0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"103"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"103"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Alteplase","description":"0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"103"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"70.9","spread":"9.8"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"39"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"64"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With a Modified Rankin Scale (mRS) Score of 0-1 at 3 Months","description":"The number of patients with a mRS score of 0-1. The mRS has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"at 3 months","groups":[{"id":"OG000","title":"Alteplase","description":"0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38"}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Symptomatic Intracranial Hemorrhage (sICH) Within 36 Hours","description":"The number of patients with sICH","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"within 36 hours","groups":[{"id":"OG000","title":"Alteplase","description":"0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"3 Months","eventGroups":[{"id":"EG000","title":"Alteplase","description":"0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour","seriousNumAffected":29,"seriousNumAtRisk":103,"otherNumAffected":91,"otherNumAtRisk":103}],"seriousEvents":[{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Asthma aggravated","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Atherosclerosis obliterans","organSystem":"Vascular disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Atrioventricular block complete","organSystem":"Cardiac disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Brain herniation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":103}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Cardiac failure NOS","organSystem":"Cardiac disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Carotid artery dissection","organSystem":"Nervous system disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":103}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":103}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Disseminated intravascular coagulation","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Haemorrhagic cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":103}]},{"term":"Infection staphylococcal","organSystem":"Infections and infestations","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Intracranial haemorrhage NOS","organSystem":"Nervous system disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Left atrial myxoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Metastases to peritoneum","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Pneumonia NOS","organSystem":"Infections and infestations","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":103}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":103}]},{"term":"Renal failure NOS","organSystem":"Renal and urinary disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Renal impairment NOS","organSystem":"Renal and urinary disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Subdural hygroma","organSystem":"Nervous system disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Tracheal obstruction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Traumatic haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Ventricular arrhythmia NOS","organSystem":"Cardiac disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]}],"otherEvents":[{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":103}]},{"term":"Ventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":103}]},{"term":"Diarrhoea NOS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":103}]},{"term":"Gastrointestinal haemorrhage NOS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":103}]},{"term":"Periproctitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":103}]},{"term":"Vomiting NOS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":103}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":103}]},{"term":"Hepatic function abnormal NOS","organSystem":"Hepatobiliary disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":103}]},{"term":"Pneumonia NOS","organSystem":"Infections and infestations","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":103}]},{"term":"Urinary tract infection NOS","organSystem":"Infections and infestations","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":103}]},{"term":"Haemorrhagic cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":103}]},{"term":"Headache NOS","organSystem":"Nervous system disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":103}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":103}]},{"term":"Neurogenic bladder","organSystem":"Renal and urinary disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":103}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":103}]},{"term":"Nasopharyngitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":103}]},{"term":"Haemorrhage subcutaneous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":103}]},{"term":"Contusion","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"5.0","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":103}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"pointOfContact":{"title":"Clinical Trials, Information Desk","organization":"Mitsubishi Tanabe Pharma Corporation","email":"cti-inq-ml@ml.mt-pharma.co.jp"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000009336","term":"Necrosis"},{"id":"D000020520","term":"Brain Infarction"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","asFound":"Ischemia","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","asFound":"Infarction","relevance":"HIGH"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Cerebral Infarction","relevance":"HIGH"},{"id":"M5484","name":"Brain Ischemia","asFound":"Brain Ischemia","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000010959","term":"Tissue Plasminogen Activator"}],"ancestors":[{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M13539","name":"Tissue Plasminogen Activator","asFound":"Patient Reported Outcomes","relevance":"HIGH"},{"id":"M13538","name":"Plasminogen","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}